/**
 * rec8_worldModelClinical.ts
 * Drop into: server/harness/recommendations/rec8_worldModelClinical.ts
 *
 * RESEARCH RADAR — RECOMMENDATION 8
 * World Model Clinical Imaging Readiness
 *
 * CONTEXT FROM THE ARTICLE:
 * LeCun's AMI Labs targets healthcare as a primary vertical for JEPA-based
 * world models. V-JEPA 2 achieves zero-shot physical task performance from
 * limited training data. The clinical equivalent would be:
 *   - ECG waveform interpretation from raw signal data
 *   - Wound/rash classification from patient-uploaded photos
 *   - X-ray interpretation as a triage support tool
 *   - Vital sign pattern recognition (SpO2, HR trends)
 *
 * CURRENT AURALYN POSITION:
 * Clinical image interpretation uses Claude's vision capabilities (general LLM).
 * A specialized world-model approach trained on clinical imaging data could
 * provide: better accuracy on specific modalities, lower cost per inference,
 * and — critically — better explainability for FDA CDS documentation.
 *
 * READINESS SIGNALS TO MONITOR:
 * 1. AMI Labs releases a healthcare-specific JEPA model
 * 2. V-JEPA fine-tuned on clinical imaging datasets (CheXpert, MIMIC-CXR)
 * 3. Apache 2.0 clinical imaging model achieving benchmark parity with GPT-4V
 * 4. FDA clears a JEPA-based clinical imaging CDS tool (establishes pathway)
 *
 * CURRENT READINESS: 1/5 — research phase, not production ready
 * MONITOR: Weekly via Research Radar
 *
 * HOW TO ADD TO researchRadar.ts:
 * Add this object to the RESEARCH_TARGETS array.
 */

export const REC8_WORLD_MODEL_CLINICAL = {
  id:            "rec8_world_model_clinical_imaging",
  name:          "Recommendation 8 — World Model Clinical Imaging",
  description:   "JEPA-based specialized models for clinical image interpretation (wound photos, rashes, ECG strips, X-rays uploaded by patients). AMI Labs has identified healthcare as a primary target vertical. V-JEPA 2 demonstrates zero-shot performance from limited training data — the clinical analog is a model trained on limited annotated clinical images that generalizes to patient-uploaded photos.",
  clinicalValue: "Patient-uploaded wound/rash photos currently rely on Claude vision (general LLM). A specialized clinical imaging model would provide higher accuracy for specific modalities, lower inference cost, and better explainability for FDA CDS documentation. For urgent care: wound assessment, rash differential, ECG rhythm interpretation.",
  auralynaImpact: "New intake channel: patient uploads photo of wound/rash/lesion → specialized model provides structured triage output → feeds into existing KB query layer → physician reviews structured output alongside AI differential. Closes the physical exam gap in telehealth triage.",
  readinessScore: 1,
  searchQueries: [
    "AMI Labs healthcare JEPA clinical imaging 2026",
    "V-JEPA clinical imaging wound rash classification Apache 2.0",
    "world model medical imaging fine-tune CheXpert MIMIC 2026",
    "FDA cleared JEPA clinical decision support imaging",
    "open source clinical imaging model ECG waveform interpretation 2026",
    "LeWorldModel healthcare application clinical",
  ],
  readinessSignals: [
    "AMI Labs releases healthcare-specific JEPA model under Apache 2.0 or similar",
    "V-JEPA 2 fine-tuned on CheXpert/MIMIC-CXR with published benchmark results",
    "Clinical imaging model achieves >85% sensitivity on wound infection classification",
    "FDA clears a JEPA-based clinical imaging CDS tool (establishes regulatory pathway)",
    "Open source model runs on single GPU with clinical imaging accuracy parity to GPT-4V",
  ],
  implementationNotes: `
    When readiness score reaches 4:
    1. Add image upload endpoint to WhatsApp intake:
       POST /api/intake/image → stores image, runs specialized model inference
    2. Output: structured JSON (lesion_type, infection_probability, urgency_level, recommended_exam)
    3. Feed structured output into KB query layer alongside complaint text
    4. Physician sees: AI image assessment + KB differential + their own review
    5. Image + AI assessment stored in audit chain (never auto-dispositioned)
    
    FDA positioning: image interpretation is CDS, not autonomous diagnosis.
    Physician reviews the model output before any clinical action — same gate as text triage.
    
    Current gap to fill manually: when patients describe a skin complaint,
    ask "can you share a photo?" via WhatsApp and use Claude vision as the
    interim solution until a specialized model is production-ready.
  `,
  estimatedBuildTime: "3-5 days once production-ready model is available",

  // THE CORRECT CURRENT APPROACH (not JEPA — Claude vision as interim)
  interimImplementation: `
    While world model clinical imaging matures, use Claude vision for patient-uploaded photos.
    
    WhatsApp intake extension:
    1. If complaint is skin/wound/eye/rash → ask patient to send a photo
    2. Twilio receives MMS → extract image → base64 encode
    3. Pass to clinical brain via llmGateway.complete() with image content block
    4. Claude vision describes: location, size, color, borders, exudate, surrounding tissue
    5. Description feeds into KB query as additional symptom data
    
    This is implementable today. It closes the physical exam gap for visual complaints
    without waiting for JEPA-based specialized models.
  `,
};

/**
 * TECHNOLOGY LANDSCAPE MONITORING
 *
 * The article identifies two parallel $1B+ anti-LLM bets:
 * - AMI Labs (LeCun): JEPA world models, $1.03B, Paris
 * - Ineffable Intelligence (Silver): RL-only superlearner, $1.1B
 *
 * Neither is immediately applicable to Auralyn's text-based clinical triage.
 * Both are worth monitoring because:
 * 1. If JEPA models for clinical imaging mature → Rec 8 above
 * 2. If RL-based clinical reasoning models emerge → potential replacement
 *    for LLM clinical brain with better sample efficiency
 * 3. If LLM scaling costs increase faster than capability (GPT-5.5 2× price
 *    increase noted in article) → Bifrost/gateway architecture becomes more
 *    valuable, not less (Auralyn already has this via Win 17)
 *
 * AURALYN'S CURRENT ARCHITECTURE IS ROBUST TO THIS LANDSCAPE:
 * - LLM Gateway with OpenAI failover → not dependent on single provider
 * - Semantic caching → partially decoupled from per-token cost increases
 * - Specialized models for retrieval (Sonnet) vs reasoning (Opus) →
 *   already implements the "right model for right task" principle LeCun advocates
 * - KB-driven clinical logic → reduces LLM dependence for structured decisions
 *
 * The article's key insight for Auralyn's business strategy:
 * "AMI targets healthcare, robotics, industrial process control" —
 * clinical AI B2B infrastructure is exactly where world models will compete.
 * Auralyn's 2-year head start in physician-validated clinical KB, audit chain,
 * and physician gate architecture is the moat that matters before JEPA-based
 * clinical tools reach production readiness.
 */

export const TECHNOLOGY_LANDSCAPE_SUMMARY = {
  jepa_clinical_readiness: "1/5 — research phase",
  rl_clinical_readiness:   "1/5 — research phase",
  llm_clinical_current:    "Production ready — correct tool for text triage",
  auralyn_moat_timeline:   "2-year window before world model clinical tools reach production",
  recommended_action:      "Build physician-validated KB and licensing relationships now",
  architecture_resilience: "LLM Gateway + semantic caching + KB-driven logic = robust to provider cost increases",
};
